Author

G. Czerwieniec

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Tankasala· 1 shared B. Feierbach· 1 shared C. Guerrier· 1 shared C. H. Tay· 1 shared C. Snyder· 1 shared C.-W. Chu· 1 shared D. Barnes· 1 shared D. Tam· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Tankasala

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

C.-W. Chu, T. Caval, F. Alisson-Silva, A. Tankasala, C. Guerrier, G. Czerwieniec, H. Laeubli, F. Schwarz

This study shows that PD-1 glycosylation variants affect the efficacy of immune checkpoint inhibitors and suggests personalized therapeutic approaches.

bioRxiv · Aug 25, 2023Immunology

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

U. Schmitz, S. A. Gilmore, D. Tam, T. L. Cheung, C. Snyder, J. Farand, R. Dick, M. Matles, J. Y. Feng, R. Ramirez, L. Li, H. Yu, Y. Xu, D. Barnes, G. Czerwieniec, , B. Feierbach

This study identifies a KDM5 inhibitor with anti-HBV activity in vitro but not in vivo, highlighting challenges in translating epigenetic therapies to viral infections.

bioRxiv · Jun 27, 2022 · PreprintPharmacology & Toxicology